
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

Bolt Biotherapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.00001 par value

(Title of Class of Securities)

097702203

(CUSIP Number)

Robert Hopfner
Pivotal bioVenture Partners Fund I UGP, 501 2nd Street, Suite 200
San Francisco, CA, 94107
(415) 697-1002

Louis Rambo
Proskauer Rose, LLP, 1001 Pennsylvania Avenue NW, Suite 600
Washington, DC, 20004-2533
(202) 416-6800

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/24/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person
Nan Fung Group Holdings Limited
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 VIRGIN ISLANDS, BRITISH

7 Sole Voting Power
Number of Shares Beneficially Owned by Each Reporting Person With: 0.00
8 Shared Voting Power
87,486.00
9 Sole Dispositive Power
0.00
10 Shared Dispositive Power
87,486.00

11 Aggregate amount beneficially owned by each reporting person
87,486.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 Percent of class represented by amount in Row (11)
4.6 %

14 Type of Reporting Person (See Instructions)
CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person
NF Investment Holdings Limited
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

6 VIRGIN ISLANDS, BRITISH

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With:

8 0.00
 Shared Voting Power

9 87,486.00
 Sole Dispositive Power

10 0.00
 Shared Dispositive Power

11 87,486.00
 Aggregate amount beneficially owned by each reporting person

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13
 Percent of class represented by amount in Row (11)

14 4.6 %
 Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person

Pivotal bioVenture Partners Fund I, L.P.

Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only

4 Source of funds (See Instructions)

WC

5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

Citizenship or place of organization

6 CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7 Sole Voting Power

8 0.00
 Shared Voting Power

9 52,556.00
 Sole Dispositive Power

Person
With: 0.00
Shared Dispositive Power
10
52,556.00
Aggregate amount beneficially owned by each reporting person
11
52,556.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12

Percent of class represented by amount in Row (11)
13
2.7 %
Type of Reporting Person (See Instructions)
14
PN

SCHEDULE 13D

CUSIP No. 097702203

Name of reporting person
1
Pivotal bioVenture Partners Fund I G.P., L.P.
Check the appropriate box if a member of a Group (See Instructions)
2
 (a)
 (b)
3
SEC use only
Source of funds (See Instructions)
4
AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5

Citizenship or place of organization
6
CAYMAN ISLANDS
Sole Voting Power
7
0.00
Number of
Shares
Beneficially 8
Owned by 52,556.00
Each
Reporting 9
Person 0.00
With: Shared Dispositive Power
10
52,556.00
Aggregate amount beneficially owned by each reporting person
11
52,556.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12

Percent of class represented by amount in Row (11)
13

2.7 %
Type of Reporting Person (See Instructions)

14

PN

SCHEDULE 13D

CUSIP No. 097702203

Name of reporting person

1

Pivotal bioVenture Partners Fund I U.G.P. Ltd.

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

Owned by

52,556.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

52,556.00

Aggregate amount beneficially owned by each reporting person

11

52,556.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

2.7 %

Type of Reporting Person (See Instructions)

14

CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person
Pivotal Partners Ltd
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 CAYMAN ISLANDS
Sole Voting Power

7
Number of Shares Beneficially Owned by Each Reporting Person With:

0.00	Sole Dispositive Power
52,556.00	Shared Dispositive Power

8
9
10
52,556.00

11 Aggregate amount beneficially owned by each reporting person
52,556.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 2.7 %
Type of Reporting Person (See Instructions)

14 CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person
Pivotal Life Sciences Holdings Limited
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization
 6 CAYMAN ISLANDS
 Sole Voting Power
 7
 Number of Shares Beneficially Owned by Each Reporting Person With: 0.00
 Shared Voting Power
 8 52,556.00
 Sole Dispositive Power
 9 0.00
 Shared Dispositive Power
 10 52,556.00
 Aggregate amount beneficially owned by each reporting person
 11 52,556.00
 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
 12

 Percent of class represented by amount in Row (11)
 13 2.7 %
 Type of Reporting Person (See Instructions)
 14 CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person
 Nan Fung Life Sciences Holdings Limited
 Check the appropriate box if a member of a Group (See Instructions)
 2
 (a)
 (b)
 3 SEC use only
 Source of funds (See Instructions)
 4 AF
 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
 5

 Citizenship or place of organization
 6 VIRGIN ISLANDS, BRITISH
 Number of Shares Beneficially Owned by Each Reporting Person With: Sole Voting Power
 7 0.00
 Shared Voting Power
 8 82,486.00
 Sole Dispositive Power
 9 0.00

10 Shared Dispositive Power

82,486.00

Aggregate amount beneficially owned by each reporting person

11

82,486.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

4.3 %

Type of Reporting Person (See Instructions)

14

CO

SCHEDULE 13D

CUSIP No. 097702203

Name of reporting person

1

Permwell Management Limited

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

Owned by

5,000.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

5,000.00

Aggregate amount beneficially owned by each reporting person

11

5,000.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

0.3 %

Type of Reporting Person (See Instructions)

14

CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person
NFLS Beta Limited
Check the appropriate box if a member of a Group (See Instructions)

2 (a)
 (b)

3 SEC use only
Source of funds (See Instructions)

4 WC
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5
Citizenship or place of organization

6 VIRGIN ISLANDS, BRITISH
Sole Voting Power

7
Number of Shares Beneficially Owned by Each Reporting Person With:

0.00	Shared Voting Power
29,930.00	Sole Dispositive Power
0.00	Shared Dispositive Power
29,930.00	

8
9
10

11 Aggregate amount beneficially owned by each reporting person
29,930.00
Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12
Percent of class represented by amount in Row (11)

13 1.6 %
Type of Reporting Person (See Instructions)

14 CO

SCHEDULE 13D

CUSIP No. 097702203

1 Name of reporting person

NFLS Platform Holdings Limited

Check the appropriate box if a member of a Group (See Instructions)

2

(a)

(b)

3

SEC use only

Source of funds (See Instructions)

4

WC

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

Citizenship or place of organization

6

CAYMAN ISLANDS

Sole Voting Power

7

0.00

Number of
Shares

Shared Voting Power

Beneficially 8

Owned by

29,930.00

Each

Sole Dispositive Power

Reporting 9

Person

0.00

With:

Shared Dispositive Power

10

29,930.00

Aggregate amount beneficially owned by each reporting person

11

29,930.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

Percent of class represented by amount in Row (11)

13

1.6 %

Type of Reporting Person (See Instructions)

14

CO

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a)

Common Stock, \$0.00001 par value

Name of Issuer:

(b)

Bolt Biotherapeutics, Inc.

Address of Issuer's Principal Executive Offices:

(c)

900 Chesapeake Drive, Redwood City, CALIFORNIA , 94063.

Item 5. Interest in Securities of the Issuer

Items 5(a)-(c) and Item 5(e) of the Schedule 13D are amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on 1,919,441 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025. In addition, Mr. Kam Chung Leung directly owns 8,684 shares of Common Stock.

(a)

The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

(b)

Except as set forth on Schedule A, which is incorporated into this Item 5(c) by reference, no Reporting Person has

(c)

effected any transaction in shares of Common Stock in the past sixty days.

- (e) On February 26, 2026, the Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Nan Fung Group Holdings Limited

Signature: /s/ Tang Chun Wai Nelson
Name/Title: Tang Chun Wai Nelson, Director
Date: 02/26/2026

NF Investment Holdings Limited

Signature: /s/ Tang Chun Wai Nelson
Name/Title: Tang Chun Wai Nelson, Director
Date: 02/26/2026

Pivotal bioVenture Partners Fund I, L.P.

Signature: By Pivotal bioVenture Partners Fund I G.P., L.P.
Name/Title: its General Partner
Date: 02/26/2026

Signature: By Pivotal bioVenture Partners Fund I U.G.P., Ltd.
Name/Title: its General Partner
Date: 02/26/2026

Signature: /s/ Robert Hopfner
Name/Title: Robert Hopfner, Authorized Signatory
Date: 02/26/2026

Pivotal bioVenture Partners Fund I G.P., L.P.

Signature: By Pivotal bioVenture Partners Fund I U.G.P., Ltd.
Name/Title: its General Partner
Date: 02/26/2026

Signature: /s/ Robert Hopfner
Name/Title: Robert Hopfner, Authorized Signatory
Date: 02/26/2026

Pivotal bioVenture Partners Fund I U.G.P. Ltd.

Signature: /s/ Robert Hopfner
Name/Title: Robert Hopfner, Authorized Signatory
Date: 02/26/2026

Pivotal Partners Ltd

Signature: /s/ Sun Xintong
Name/Title: Sun Xintong, Director
Date: 02/26/2026

Pivotal Life Sciences Holdings Limited

Signature: /s/ Sun Xintong
Name/Title: Sun Xintong, Director
Date: 02/26/2026

Nan Fung Life Sciences Holdings Limited

Signature: /s/ Sun Xintong
Name/Title: Sun Xintong, Director

Date: 02/26/2026

Permwell Management Limited

Signature: /s/ Tang Chun Wai Nelson

Name/Title: Tang Chun Wai Nelson, Director

Date: 02/26/2026

NFLS Beta Limited

Signature: /s/ Sun Xintong

Name/Title: Sun Xintong, Director

Date: 02/26/2026

NFLS Platform Holdings Limited

Signature: /s/ Sun Xintong

Name/Title: Sun Xintong, Director

Date: 02/26/2026

Schedule A

Fund	Date	Transaction	Number of shares	Price
Pivotal bioVenture Partners Fund I, L.P.	02/17/2026	Sale	510	\$4.9893 ⁽¹⁾
NFLS Beta Limited		Sale	290	
Pivotal bioVenture Partners Fund I, L.P.	02/18/2026	Sale	5,076	\$4.6478 ⁽²⁾
NFLS Beta Limited		Sale	2,891	
Pivotal bioVenture Partners Fund I, L.P.	02/19/2026	Sale	4,751	\$4.8762 ⁽³⁾
NFLS Beta Limited		Sale	2,685	
Pivotal bioVenture Partners Fund I, L.P.	02/20/2026	Sale	828	\$5.1386 ⁽⁴⁾
NFLS Beta Limited		Sale	472	
Pivotal bioVenture Partners Fund I, L.P.	02/23/2026	Sale	956	\$4.9775 ⁽⁵⁾
NFLS Beta Limited		Sale	544	
Pivotal bioVenture Partners Fund I, L.P.	02/24/2026	Sale	828	\$5.0017 ⁽⁶⁾
NFLS Beta Limited		Sale	472	
Pivotal bioVenture Partners Fund I, L.P.	02/25/2026	Sale	3,228	\$4.9799 ⁽⁷⁾
NFLS Beta Limited		Sale	1,838	
Pivotal bioVenture Partners Fund I, L.P.	02/26/2026	Sale	9,748	\$4.6604 ⁽⁸⁾
NFLS Beta Limited		Sale	5,552	

¹ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.93 to \$5.03 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

² The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.50 to \$5.15 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

³ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.70 to \$5.25 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

⁴ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$5.03 to \$5.23 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

⁵ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.92 to \$5.04 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

⁶ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.92 to \$5.12 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

⁷ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.90 to \$5.07 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range

⁸ The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$4.52 to \$5.11 inclusive. The reporting persons undertake to provide the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within such range